Performance

GMAB +94.70%

Watchlist

Select an item

RETURNS	1D	YTD	1Y	5Y Ann.	Max DD	Sharpe	Div. Yield
GMAB	+4.05%	+81.17%	+94.70%	+3.72%	-32.51%	1.60	0.00%

Summary

GMAB at a glance

GMAB returned +94.70% over the past year and +3.72% a year over five years. Its worst drop in that year was -32.51%, smaller than 52% of stocks on Redstone, and its Sharpe ratio of 1.60 beats 94% of stocks on Redstone. It pays no dividends.

Ranking

How GMAB ranks

Current Drawdown

-2.60%

Rolling Volatility

103.34%

Actions

Metrics

Risk Indicators

Alpha63.97%

Beta0.92x

Sharpe1.60

Sortino3.20

Omega1.38

Calmar2.91

Martin4.45

Profile

About GMAB

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect.

Sector: Health Care
Market cap: $34.3B
Listed: Oct 2010
Employees: 3,119
Website: genmab.com

Comparisons

GMAB: Genmab A/S

GMAB at a glance

How GMAB ranks

Current Drawdown

Rolling Volatility

About GMAB

Related comparisons